Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-Escalation Study in Healthy Volunteers to Evaluate the Safety and Tolerability Profiles of Careseng 1370

NCT03974516 is registered in ClinicalTrials.gov with i Cure Biotech Co., Ltd. as lead sponsor.

NCT NCT03974516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03974516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-Escalation Study in Healthy Volunteers to Evaluate the Safety and Tolerability Profiles of Careseng 1370
Lead sponsor
i Cure Biotech Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
August 10, 2020
Completion date
March 11, 2022
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced myelosuppression